

# Ying Huang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/127032/publications.pdf>

Version: 2024-02-01

7  
papers

470  
citations

1478505

6  
h-index

1720034

7  
g-index

7  
all docs

7  
docs citations

7  
times ranked

623  
citing authors

#	ARTICLE	IF	CITATIONS
1	An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED. <i>Nature Chemical Biology</i> , 2017, 13, 381-388.	8.0	259
2	Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 2215-2226.	6.4	86
3	Structure-Guided Design of EED Binders Allosterically Inhibiting the Epigenetic Polycomb Repressive Complex 2 (PRC2) Methyltransferase. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 415-427.	6.4	52
4	Discovery and Molecular Basis of a Diverse Set of Polycomb Repressive Complex 2 Inhibitors Recognition by EED. <i>PLoS ONE</i> , 2017, 12, e0169855.	2.5	36
5	Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 5317-5333.	6.4	24
6	Split luciferase-based biosensors for characterizing EED binders. <i>Analytical Biochemistry</i> , 2017, 522, 37-45.	2.4	7
7	Preclinical pharmacokinetics and metabolism of MAK683, a clinical stage selective oral embryonic ectoderm development (EED) inhibitor for cancer treatment. <i>Xenobiotica</i> , 2022, 52, 65-78.	1.1	6